Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVEAL: venetoclax + acalabrutinib retreatment after prior first-line venetoclax + anti-CD20 therapy in relapsed CLL/SLL
NL-OMON52450Phase 2Recruiting
- Sponsor
- HOVON
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of acalabrutinib and venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by HOVON. Primary endpoint: Undetectable minimal residual disease in bone marrow after 26 cycles. Started Jun 2021; status: recruiting.
02
Drugs
acalabrutinibvenetoclax
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on NL-OMON52450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52450.